SPRY — ARS Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $824.58m
- $600.95m
- $0.03m
- 45
- 10
- 80
- 41
Annual cashflow statement for ARS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24 | -32.9 | -89.5 | -34.7 | -54.4 |
| Depreciation | |||||
| Non-Cash Items | 1.23 | 3.74 | 20.3 | 7.04 | 2.36 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.3 | -2.63 | 1.6 | -12.8 | -7.33 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -18.9 | -31.2 | -66.8 | -40.1 | -59.3 |
| Capital Expenditures | -0.096 | -0.917 | -1.37 | -0.199 | -0.175 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -65.1 | — | -87 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.096 | -0.917 | -66.5 | -0.199 | -87.2 |
| Financing Cash Flow Items | — | -2.61 | 0 | 199 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 8.61 | 409 | 0.614 | 191 | 6.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.4 | 376 | -133 | 150 | -140 |